Almost 10 years ago, researchers at the Institut Pasteur began developing vaccines to treat chronic pain in animals, especially dogs, cats and horses.
The Institut Pasteur and the start-up Xeptiva Therapeutics have developed a vaccine for the treatment of pain in pets.
The product focuses primarily on diseases that have chronic inflammation as a common denominator.
Almost 10 years ago, researchers at the Institut Pasteur began developing vaccines to treat chronic pain in animals, especially dogs, cats and horses.
A few years ago, the scientists figured out that the product could be patented and commercialized, so they teamed up with entrepreneur Josefina Correa and investor Ángel Santiago Flores and created the biotech start-up.
The goal of the initiative is to cure diseases that have chronic inflammation as a common denominator. This immunotherapy is a type of treatment that stimulates the body’s natural defenses.
During 2022 the researchers, together with the company’s veterinary team, carried out clinical trials on dogs suffering from chronic pain and which, to date, had not received effective treatment.
This year, following an agreement with the Faculty of Veterinary Medicine, Xeptiva will start controlled studies in a larger number of animals suffering from chronic pain in order to confirm the efficacy and safety of the product.
Although the goal is to combat this disease in pets and launch the product in the veterinary market, the researchers see that the developed technology could be applied to human use since it is the same type of pathology that is affected.
The Institut Pasteur and the start-up Xeptiva Therapeutics have developed a vaccine for the treatment of pain in pets.
The product focuses primarily on diseases that have chronic inflammation as a common denominator. pic.twitter.com/KdY7uOKvf1
– Telemundo (@TelemundoUY) January 3, 2023
